Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Secondary to Toxoplasmic Retinochoroiditis: A Case Series

References

• Willerson D, Aaaberg TM Sr, Reeser F, Meredith TA. Unusual ocular presentation of acute toxoplasmosis. Br J Ophthalmol 1977;61:693–698
   PubMed Web of Science ®Google Scholar
• Fine SL, Owens SL, Haller JA, et al. Choroidal neovascularization as a late complication of ocular toxoplasmosis. Am J Ophthalmol 1981;91:318–322
   Google Scholar
• Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol 2004;48:386–391
   PubMed Web of Science ®Google Scholar
• Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 2001;119:198–207
   PubMed Web of Science ®Google Scholar
• Adan A, Mateo C, Wolley-Dod C. Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 2003;135:386–387
   Google Scholar
• Rosenfeld PJ, Saperstein DA, Bressler NM, et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled open-label 2-year study. Ophthalmology 2004;111:1725–1733
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372
   PubMed Web of Science ®Google Scholar
• Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960–963
   PubMed Web of Science ®Google Scholar
• Teixeira A, Moraes N, Farah ME, Bonomo PP. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 2006;84:835–836
   PubMedGoogle Scholar
• Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol 2004;48:386–391
   PubMed Web of Science ®Google Scholar
• Augsburger JJ, Benson WE. Subretinal neovascularisation in chronicuveitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980;215:43–51
   Google Scholar
• Goshorn EB, Hoover DL, Eller AW, et al. Subretinal revascularization in children and adolescents. J Paediatr Ophthalmol Strabismus 1995;32:178–182
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Moore AT. Choroidal neovascularisation in children. Br J Ophthalmol 2008;92:451–454
   Google Scholar
• Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158–3164
   PubMed Web of Science ®Google Scholar
• Perentes Y, Chan CC, Bovey E, et al. Massive vascular endothelial growth factor (VEGF) expression in Eales’ disease. Klin Monatsbl Augenheilk 2002;219:11–14
   Google Scholar
• Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262–269
   PubMed Web of Science ®Google Scholar
• Adan A, Mateo C, Navarro R, et al. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180–1186
   PubMed Web of Science ®Google Scholar
• Guthoff R, Goebel W. Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis. Acta Ophthalmol 2009;87(6):688–690
   Google Scholar
• Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. International Ophthalmol 2008;28:311–316
   Google Scholar
• Lin CJ, Chen SN, Hwang JF, Hu PS. Successful treatment of toxoplasmosis-associated choroidal neovascular lesions with bevacizumab and antiparasitic therapy. Retinal Cases & Brief Reports 2011;5(4):348–351
   Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372
   PubMed Web of Science ®Google Scholar
• Nessi F, Guex-Crosier Y, Ambresin A, Zografos L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to toxoplasmic chorioretinal scar. Klin Monatsbl Augenheilkd 2004;221:371–373
   PubMed Web of Science ®Google Scholar
• Oliveira LB, Reis PA. Photodynamic therapy-treated choroidal neovascular membrane secondary to toxoplasmic retinochoroiditis. Graefes Arch Clin Exp Ophthalmol 2004;242:1028–1030
   Google Scholar
• Mauget-Faysse M, Mimoun G, Ruiz-Moreno JM, et al. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina 2006;26:396–403
   PubMed Web of Science ®Google Scholar
• Wirthlin R, Song A, Song J, Rosenfeld PJ. Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch Ophthalmol 2006;124:741–743
   PubMedGoogle Scholar